<DOC>
	<DOCNO>NCT00098774</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving rituximab combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well rituximab give combination chemotherapy work treat patient newly diagnose primary CNS lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Newly Diagnosed Primary CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate remission induction therapy combination high-dose methotrexate ( HDMTX ) , temozolomide , rituximab 4 month . Secondary - Determine safety feasibility consolidation therapy comprise cytarabine etoposide administer induction therapy patient . - Determine percentage patient achieve durable ( complete partial ) remission treat regimen . - Determine relapse-free survival complete response patient treat regimen . - Correlate molecular marker outcome patient treated regimen . - Determine effect regimen neurological function patient . OUTLINE : This multicenter study . - Induction Chemotherapy : All induction therapy course repeat every 28 day . - Courses 1-3 : Patients receive high-dose methotrexate IV 4 hour day 1 15 , leucovorin calcium IV orally every 6 hour begin day 2 16 continue blood level methotrexate safe range , oral temozolomide day 7-11 . Patients also receive rituximab* IV day 3 , 10 , 17 , 24 course 1 day 3 10 course 2 ( total 6 dos ) . NOTE : *Patients diagnose T-cell primary CNS lymphoma receive rituximab . - Course 4 : Patients receive oral temozolomide day 7-11 , high-dose methotrexate IV 4 hour day 15 , leucovorin calcium IV orally every 6 hour begin day 16 continue blood level methotrexate safe range . Patients achieve complete response complete response unconfirmed proceed consolidation therapy . - Consolidation therapy I ( course 5 ) : Beginning 4 week start course 4 , patient receive high-dose methotrexate IV 4 hour day 1 , leucovorin calcium IV orally every 6 hour begin day 2 continue blood level methotrexate safe range , oral temozolomide day 7-11 . - Consolidation therapy II ( course 6 ) : Beginning 3-5 week start course 5 , patient receive cytarabine IV 2 hour twice daily etoposide IV 12 hour twice daily day 1-4 filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously begin day 14 continue blood count recover . Treatment continue absence disease progression . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 27-45 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose primary CNS lymphoma confirm 1 follow method : Brain biopsy resection Cerebrospinal fluid ( CSF ) cytology Positive CSF cytology without measurable intracranial disease No evidence systemic nonHodgkin 's lymphoma CT scan MRI chest , abdomen , pelvis AND bilateral bone marrow biopsy unilateral biopsy 2cm core biopsy specimen negative extracerebral source lymphoma Measurable contrastenhancing disease MRI brain spine ( plus gadolinium ) unless CSF cytology positive No evidence pleural effusion ascites PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hepatic ALT AST ≤ 2 time upper limit normal Bilirubin ≤ 2 mg/dL Renal Creatinine clearance ≥ 50 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study participation HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Concurrent steroid management symptom relate lymphoma allow Radiotherapy No concurrent palliative radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>